{
  "slug": "uncommon-therapeutics",
  "name": "Uncommon Therapeutics",
  "yc_id": 29959,
  "batch": "Winter 2025",
  "website": "https://uncommontherapeutics.com",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:33:42.258142",
    "website": "https://uncommontherapeutics.com",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 2941.65,
      "final_url": "https://www.uncommontherapeutics.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:33:45.199808"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "uncommontherapeutics.com",
      "registrar": "GoDaddy.com, LLC",
      "creation_date": "2023-11-16T05:39:05",
      "expiration_date": "2025-11-16T05:39:05",
      "domain_age_days": 700,
      "domain_age_years": 1.9,
      "name_servers": [
        "CONNECT1.SQUARESPACEDNS.COM",
        "CONNECT2.SQUARESPACEDNS.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": false,
      "x_frame_options": true,
      "x_content_type_options": true,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 50,
      "server": "Squarespace"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:42:11.660658",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:52:49.452457",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "Precision medicine and personalized therapeutics",
        "Gene therapy and rare disease focus",
        "Polytherapy approaches for complex conditions"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Personal founder motivation combined with innovative polytherapy approach for rare diseases",
      "differentiation": "Founder-driven mission with direct patient impact experience and multi-drug combination strategy",
      "competitive_advantages": [
        "Deep personal understanding of patient needs",
        "Polytherapy innovation approach"
      ],
      "competitive_vulnerabilities": [
        "Small team size",
        "Early stage with unproven clinical results"
      ]
    },
    "business_model": {
      "revenue_model": "Pharmaceutical licensing and partnerships",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "pre-seed",
      "growth_indicators": [
        "Y Combinator backing",
        "Founder's tech entrepreneurship background"
      ],
      "growth_bottlenecks": [
        "Regulatory approval timelines",
        "Clinical trial funding requirements"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Long drug development cycles",
        "Regulatory approval uncertainty",
        "High capital requirements for clinical trials"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Passionate founder with personal stake",
        "Large addressable market for rare diseases",
        "Potential for multiple billion-dollar therapeutics"
      ],
      "concerns": [
        "Very early stage with no proven results",
        "Extremely long development timelines"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Biogen",
        "Sarepta Therapeutics"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure additional scientific talent",
        "Establish key pharmaceutical partnerships"
      ],
      "expansion_opportunities": [
        "Platform approach for other rare genetic diseases",
        "Licensing polytherapy methodology"
      ]
    },
    "tokens_used": {
      "input": 721,
      "output": 531,
      "total": 1252,
      "estimated_cost": 0.010128
    },
    "status": "success"
  },
  "phase8_complete": true
}